Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108,512 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.
Zhou C, Wang Z, Sun M, Cao L, Ma Z, Wu R, Yu Y, Yao W, Sun S, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Hu C, Liu J, Liu Y, Wang M, Li X, Sun P, Shu Y, Zhou J, Li J, Gu K, Wang C, Zhao H, Zhang Y, Liu C, Wang J, Chen R, Qin M, Wang H, Yang J. Zhou C, et al. Among authors: chen j, chen r, chen x. Nat Cancer. 2023 Jun;4(6):860-871. doi: 10.1038/s43018-023-00578-z. Epub 2023 Jun 15. Nat Cancer. 2023. PMID: 37322367 Clinical Trial.
Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway).
Jiao XD, Qin BD, Wang Z, Liu K, Wu Y, Ling Y, Qin WX, Wang MM, Yuan LY, Barreto SG, Kim AW, Mak K, Li H, Xu YY, Qiu XM, Wu M, Jin M, Xu LC, Zhong Y, Yang H, Chen XQ, Zeng Y, Shi J, Zhu WY, Ding QQ, Jia W, Liu SF, Zhou JJ, Shen H, Yao SH, Guo ZJ, Li T, Zhou PJ, Dong XW, Lu WF, Coleman RL, Akce M, Akladios C, Puccetti F, Zang YS. Jiao XD, et al. Front Oncol. 2023 Feb 23;13:860711. doi: 10.3389/fonc.2023.860711. eCollection 2023. Front Oncol. 2023. PMID: 36910668 Free PMC article.
Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study.
Zhang D, Liu X, Shen F, Zhao D, Shi Y, Zhang H, Liu J, Gao X, Chen M, Zhao J, Zhong W, Gao J, He M, Liu Y, Yang X, Qin J, Tang Y, Mu X, Gu Y, Zhang S, Chen X, Pang L, Meng Q, Guo Y, Zhang Y, Li W, Xing P, Cheng Y, Xin T, Li Q, Li Y, Chen J, Gao F, Jin B, Rossi A, Adachi H, Guerrera F, Husain H, Xu Y, Wang M. Zhang D, et al. Among authors: chen j, chen m, chen x. Transl Lung Cancer Res. 2023 Nov 30;12(11):2229-2244. doi: 10.21037/tlcr-23-577. Epub 2023 Oct 26. Transl Lung Cancer Res. 2023. PMID: 38090527 Free PMC article.
HER2 transmembrane domain mutation: comprehensive characteristics and real-world evidence of treatment response in Chinese lung adenocarcinoma.
Jia Z, Xing J, Li J, Wang W, Wang Y, Song Y, Yang X, Xue J, Ye J, Li B, Han-Zhang H, Zhao J, Zhang X, Peng F, Chen F, Chen X, Lu Y, Ying S, Wu D, Zhang X, Ma C, Lai L, Ma S, Liang D, Liu P, Li X, Liang N, Li S. Jia Z, et al. Among authors: chen f, chen x. Transl Lung Cancer Res. 2021 Mar;10(3):1383-1396. doi: 10.21037/tlcr-21-107. Transl Lung Cancer Res. 2021. PMID: 33889517 Free PMC article.
Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study.
Zhang S, Zhu L, Xia B, Chen E, Zhao Q, Zhang X, Chen X, Chen X, Ma S. Zhang S, et al. Among authors: chen e, chen x. Cancer Commun (Lond). 2018 May 22;38(1):28. doi: 10.1186/s40880-018-0303-2. Cancer Commun (Lond). 2018. PMID: 29789021 Free PMC article. Clinical Trial.
108,512 results
You have reached the last available page of results. Please see the User Guide for more information.